If You Invested in Singular Genomics Systems, Inc. (OMIC)

Singular Genomics Systems, Inc. (formerly trading on Nasdaq under the symbol OMIC) is described as a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. According to the company’s public communications, its platforms are designed to empower researchers and clinicians by producing fast and accurate genomic and spatial multiomic data that can be applied to science, medicine and precision healthcare research.

The company’s primary commercially available product, as described in its news releases, is the G4® Sequencing Platform. This benchtop genomic sequencer is characterized by the company as a powerful and highly versatile system intended to deliver rapid and accurate sequencing results. In addition to this instrument, Singular Genomics reports that it is developing the G4X™ Spatial Sequencer, a platform that is expected to leverage the same proprietary sequencing technology as the G4 and apply it as an in situ readout for multiple molecular modalities.

Core technologies and platforms

In its public descriptions, Singular Genomics highlights two core platforms:

• G4® Sequencing Platform – Described as a benchtop genomic sequencer designed to produce fast and accurate results. Company materials emphasize its versatility for different sequencing applications and its role in generating data for research customers.
• G4X™ Spatial Sequencer – Described as under development, this system is expected to provide spatial sequencing and multiomics capabilities. Singular Genomics states that the G4X will apply its proprietary sequencing technology as an in situ readout for transcriptomics, proteomics and fluorescent H&E (H&E) in tissue, with spatial context and on the same platform as the G4.

Company news releases further describe the G4X as a spatial multiomics and spatial biology platform designed for high-throughput use. Singular Genomics has reported early access placements of the G4X at institutions such as Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, where researchers are using the system for applications including 3D spatial analyses, immune-oncology focused panels and retrospective clinical cohorts.

Spatial multiomics and Direct-Seq technology

Singular Genomics has publicly presented data on the G4X platform’s performance in formalin-fixed, paraffin-embedded (FFPE) tissue samples, including lung, kidney, colon and breast tissues. According to the company, these studies demonstrate high sensitivity, specificity and reproducibility across immune-oncology-focused panels, enabling spatial insights into both cancerous and healthy tissues.

The company also describes a proprietary Direct-Seq technology. In its news, Singular Genomics reports that Direct-Seq enables sequencing of variable regions within cells in tissue and has been used to demonstrate accurate T-cell receptor and B-cell receptor sequencing in FFPE tonsil samples. The company links this capability to single-cell immune repertoire profiling in a spatial context, with applications in immune-oncology and tumor-immune interaction studies.

Applications in research and medicine

Across its announcements, Singular Genomics positions its technologies for use by researchers and clinicians working in areas such as cancer research, immune-oncology, spatial biology and broader genomic studies. The company notes that its platforms are used to generate multiomic data, including transcripts, proteins and fluorescent H&E signals, from tissue samples. It has highlighted use cases such as:

• 3D multi-omic reconstruction and niche detection from serial FFPE sections.
• Spatial neighborhood analyses of immune-tumor interactions.
• Identification of cell populations and complex tumor-immune interactions with single-cell precision.

Singular Genomics has also described a Spatial Technology Access Services program, through which researchers can submit samples and obtain data generated using the company’s technology. This program has been associated in company communications with early interest in spatial sequencing and with validation of the G4X platform’s capabilities.

Corporate status and ownership

Based on its public announcements, Singular Genomics previously traded on the Nasdaq Capital Market under the ticker symbol OMIC. The company disclosed that it received a letter from Nasdaq in the past regarding non-compliance with the minimum bid price requirement and later reported that it had regained compliance with this requirement after effecting a 1-for-30 reverse stock split of its common stock. The reverse split was described as intended to help the company meet Nasdaq’s minimum bid price standard.

Subsequently, Singular Genomics announced that it had entered into a definitive merger agreement under which an affiliate of Deerfield Management Company, L.P. would acquire Singular Genomics in an all-cash transaction. The company later reported the closing of the acquisition by Deerfield, stating that Deerfield acquired all outstanding shares of Singular Genomics common stock not already owned by Deerfield. Following the satisfaction of customary conditions, including stockholder approval, Singular Genomics stated that it now operates as a private company, that trading of its common stock has been suspended on Nasdaq, and that it has requested delisting from Nasdaq.

Business context for investors and researchers

For investors and researchers reviewing the historical OMIC listing, it is relevant that Singular Genomics describes itself as a company focused on developing NGS and spatial multiomics technologies, with a commercially available sequencing platform (G4) and a spatial sequencer (G4X) under development. The company’s mission, as stated in multiple news releases, is to empower researchers and clinicians to advance science and medicine.

Because Singular Genomics has completed its acquisition by an affiliate of Deerfield and reports that it operates as a private company with suspended trading and a requested delisting from Nasdaq, the OMIC ticker now primarily represents the historical public listing of Singular Genomics Systems, Inc. Information associated with OMIC on public markets should therefore be understood in that historical context.